What Kisspeptin can actually do for libido and sexual function

Kisspeptin started life as a fertility peptide, discovered because a handful of people with a broken KISS1R receptor turned out to have no functioning reproductive system at all. Since then, two placebo-controlled human trials out of Imperial College London have measured exactly what it does for libido and sexual function in real people. Short answer: kisspeptin measurably increases sexual desire and arousal in both men and women, works even when your hormone labels come back normal, and it does this without tanking your mood.

I get this question constantly from guys whose testosterone panel is fine and the drive still isn't there, and from women whose labs look normal but desire has quietly disappeared. Kisspeptin is one of the few peptides with actual controlled human data on that exact problem, so it's worth walking through what the trials found and what a real protocol looks like.

What kisspeptin actually is

KISS1R is the receptor kisspeptin binds to, and it sits at the very top of what's called the HPG axis, the hormonal chain that runs from your brain down to your testes or ovaries. Kisspeptin fires first, tells GnRH neurons to release, GnRH tells your pituitary to release LH and FSH, and those hormones tell your gonads to make testosterone or estrogen. But KISS1R isn't only in that reproductive chain. It's also expressed directly in the limbic system, the part of your brain that processes emotion, reward, and sexual arousal. That second location is why kisspeptin can move the needle on desire through a completely separate route from the hormone cascade. For the full mechanism rundown and dosing math, the kisspeptin encyclopedia entry covers it in depth. This piece stays narrow: what the sexual-function data actually shows.

What the human trials on libido and sexual function actually found

Imperial College London ran two matching studies, one in men and one in women, both randomized, double-blind, and placebo-controlled. In the men's trial, 32 men with diagnosed low sexual desire received kisspeptin infusions and showed significantly more brain activity in the sexual-processing network, plus a measurable increase in physical arousal response compared to placebo.

The women's trial ran the same design in premenopausal women with the same diagnosis. Kisspeptin changed activity in the specific brain regions tied to inhibition and social processing during sexual and emotional stimuli, and desire scores on the exploratory subscale moved in the right direction. Neither study reported serious side effects.

Here's the part that surprised even the researchers: in the women's trial, LH and FSH went up, proof the HPG axis fired, but estradiol, progesterone, and testosterone did not change at all during the short infusion window. Desire and brain activity shifted anyway. That's the whole finding in one sentence: kisspeptin's effect on libido isn't just downstream hormone math.

Why it works even when your labs look normal

This is the part I think gets missed the most. A kisspeptin bolus raises LH roughly two to three times over baseline, which is the classic fertility-hormone effect everyone expects. But the brain-region changes in both trials happened independent of that hormone shift. Kisspeptin acts directly on KISS1R receptors sitting in your limbic system, the same real estate involved in bonding, reward, and arousal circuits, and it does that on its own schedule, separate from whatever your ovaries or testes end up producing.

That's the mechanism behind a pattern I hear constantly: normal testosterone, normal estrogen, normal everything on paper, and desire is still gone. If the deficit sits at the level of the signal itself, testosterone replacement or estrogen therapy alone won't necessarily fix it, because it's treating a different layer of the cascade than the one that's actually failing.

Mood: the other half of the picture

Low libido and mood problems tend to travel together, so it matters that kisspeptin's mood data is clean. An earlier Imperial study found kisspeptin boosted activity in reward-related brain regions and reduced negative mood responses during the infusion. A newer 2025 trial went looking specifically for an anxiety signal, since ramping up a reproductive-axis hormone sounds like something that could jack up stress hormones, and found kisspeptin does not affect anxiety in either direction. It's not calming. It's not agitating. Neutral on anxiety and positive on mood and reward response is about as clean a safety picture as you get from a peptide this early in its research life.

Real-world dosing

The trials used IV infusions in a clinical setting, which isn't what anyone running this at home is doing. The community-standard approach for Kisspeptin-10 is subcutaneous, commonly 100 to 300 mcg per dose. Because the whole mechanism depends on pulsatile signaling, meaning the brain expects bursts and not a steady drip, dosing more than twice a week is the norm, and a lot of people run it daily or split into a morning and evening dose. For a straight libido use case, some people trial it for one to two weeks and judge from there. For broader HPG-axis support, four to twelve weeks with a lab recheck of LH, FSH, and your relevant sex hormone is the more common window.

Now the part my lawyer makes me say, and he's right about it:

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Who this actually fits

If your labs are clean and your libido still isn't there, kisspeptin is one of the few tools with controlled human trial data on that exact scenario, in both men and women. It's not a stand-in for TRT or HRT when the gonads themselves are the problem, and it works through a different mechanism than something like PT-141, which acts on the melanocortin system instead. If you're new to peptides generally and want to know whether any of this is safe to explore, this rundown on peptide safety is a good place to start before picking a specific compound.

I've watched this pattern play out with more than a few people who spent months chasing a libido problem through hormone panels that kept coming back normal. The Imperial data is the first real evidence that the signal itself can be the thing worth addressing.